Bessemer Group’s Vir Biotechnology VIR Stock Holding History

Bessemer Group’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2K	Hold	207	–	–	﹤0.01%	2435
2026 Q1	$2K	Hold	207	–	–	﹤0.01%	2403
2025 Q4	$1K	Buy	+207	New	+$1.23K	﹤0.01%	2502
2025 Q3	–	Sell	-60	Closed	–	–	2742
2025 Q2	$0	Hold	60	–	–	﹤0.01%	2645
2025 Q1	$0	Buy	+60	New	+$533	﹤0.01%	2735
2024 Q4	–	Sell	-140	Closed	-$1K	–	2706
2024 Q3	$1K	Buy	+140	New	+$1.22K	﹤0.01%	2565
2023 Q3	–	Sell	-64	Closed	-$2K	–	2349
2023 Q2	$2K	Buy	+64	New	+$1.61K	﹤0.01%	2086
2023 Q1	–	Sell	-140	Closed	-$4K	–	2083
2022 Q4	$4K	Hold	140	–	–	﹤0.01%	1689
2022 Q3	$3K	Buy	+140	New	+$3.56K	﹤0.01%	1876

Other funds holding VIR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Bessemer Group's VIR Position: Q2 2026 in Review

Bessemer Group held its Vir Biotechnology (VIR) position steady in Q2 2026 at 207 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #2435.

Bessemer Group first reported a position in VIR in Q3 2022 and has held it in 9 quarters since. The position peaked at $4K in Q4 2022. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

Bessemer Group held 207 shares of Vir Biotechnology worth $2K as of Q2 2026.
Bessemer Group left its Vir Biotechnology share count unchanged in Q2 2026.
Vir Biotechnology made up ﹤0.01% of Bessemer Group's portfolio in Q2 2026, its #2435 holding.
Bessemer Group first reported a position in Vir Biotechnology in Q3 2022 and has held it in 9 quarters since.
Bessemer Group's Vir Biotechnology position peaked at $4K in Q4 2022.
237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.